RAD June 2021 Virtual Conference Abstracts & Posters

Abstracts will be published in the British Journal of Dermatology in Q4/2021. A link will be posted here when the abstracts have been published.

#439 - Differences in Psychometric Properties of Clinician and Patient-reported Outcome Measures for Atopic Dermatitis By Race and Skin Tone: A Systematic Review

Trisha Kaundinya BS, Uros Rakita MSc, Armaan Guraya BA, Donna Maria Abboud BS, Emily Croce MSN, APRN, CPNP-PC, Jacob P. Thyssen, MD, PHD, MPH, Andrew Alexis, MD, MPH, Jonathan I. Silverberg MD, PhD, MPH


#440 - COVID-19 in tralokinumab-treated patients with moderate-to-severe atopic dermatitis: case series from the ECZTEND long-term extension trial

Andrew Blauvelt, Andrew Pink, Margitta Worm, Richard Langley, Antonio Costanzo, Le Gjerum, Emilie Jorgensen, Joshua Corriveau, Emma Guttman-Yassky


#443 - Efficacy and Safety of Crisaborole in Patients With Mild-to-Moderate Atopic Dermatitis With and Without Comorbid Allergies or Asthma

Peter Lio, Michael J. Cork, Michael S. Blaiss, Aharon Kessel, Wendy C. Cantrell, John L. Werth, Michael O’Connell, Chuanbo Zang, Liza Takiya


#447 - Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: combined results from two Phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2)

Andrew Blauvelt, Andreas Wollenberg, Andrew Pink, Ketty Peris, April Armstrong, Lynda Spelman, Hidehisa Saeki, Charles Lynde, Pedro Herranz, Sebastien Barbarot, Eric Simpson


#448 - Neutralizing interleukin-13 with tralokinumab shifts the molecular phenotype of lesional skin towards that of non-lesional skin and restores skin barrier abnormalities

Emma Guttman-Yassky, Matthew Zirwas, Kenji Kabashima, Delphine Staumont-Sallé, Petra Amoudruz, Mads Røpke, Ana Pavel


#449 - Neutralizing interleukin-13 increases skin microbial diversity: results from a Phase 3, randomized, double-blind, placebo-controlled trial of tralokinumab in adult patients with atopic dermatitis

Thomas Bieber, Lisa A. Beck, Andrew Pink, Hidehisa Saeki, Lawrence Eichenfield, Thomas Werfel, Anders Rosholm, Mads Røpke, Amy Paller


#451 - Impact of targeting interleukin-13 on Staphylococcus aureus colonization: results from a Phase 3, randomized, double-blind, placebo-controlled trial with tralokinumab in adult patients with atopic dermatitis

Thomas Bieber, Lisa A Beck, Andrew Pink, Hidehisa Saeki, Lawrence Eichenfield, Thomas Werfel, Anders Rosholm, Mads Røepke, Amy Paller


#453 - Long-term improvements observed in tralokinumab-treated patients with moderate-to-severe atopic dermatitis: an ECZTEND interim analysis

Andrew Blauvelt, Jean-Philippe Lacour, Darryl Toth, Vivian Laquer, Stefan Beissert, Andreas Wollenberg, Pedro Herranz, Andrew Pink, Ketty Peris, Stine Fangel, Hidehisa Saeki


#460 - Impact of Lebrikizumab on Patient-reported Outcomes in Atopic Dermatitis: Prospective and Post Hoc Analyses of a Phase 2b Clinical Trial Demonstrate Clinically Meaningful Improvements

E. Guttman-Yassky, A. Blauvelt, L. Eichenfield, A. Paller, A. Armstrong, J. Drew, R. Gopalan, and E. Simpson


#463 - MOSAIC: Monitoring of Scratch via Accelerometry in Children with Atopic Dermatitis

Carrie A Northcott, Junrui Di, Yiorgos Christakis, Nikhil Mahadevan, Nina Shaafi Kabiri, Riley J Phelps, Madisen K Wicker, Robert Koehler, Jonathan Bruno, Mar Santamaria, Yao Zhang, Kevin Thomas


Page 1 of 7
Results 1 - 10 of 65
© 2021 The Foundation for Dermatology Education.
The Foundation for Dermatology Education is a registered 501(c)(3) nonprofit organization located in Chicago, IL.